369 / 412
3. Shaheen NJ, Hansen RA, Morgan DR, et al. The burden of
gastrointestinal and liver diseases, 2006.
Am J Gastroenterol
2006;101:
2128–2138.
4. Frye JW, Vaezi MF. Extraesophageal GERD.
Gastroenterol Clin North Am
2008;37:845–858, ix.
5. Qadeer MA, Phillips CO, Lopez AR, et al. Proton pump inhibitor therapy
for suspected GERD-related chronic laryngitis: a meta-analysis of
randomized controlled trials.
Am J Gastroenterol
2006;101:2646–2654.
6. Kahrilas PJ, Shaheen NJ, Vaezi MF. American Gastroenterological Associ-
ation Institute technical review on the management of gastroesophageal
reflux disease.
Gastroenterology
2008;135:1392–413, 413 e1–5.
7. Park W, Vaezi MF. Esophageal impedance recording: clinical utility and
limitations.
Curr Gastroenterol Rep
2005;7:182–189.
8. Sifrim D, Blondeau K. Technology insight: the role of impedance testing
for esophageal disorders.
Nat Clin Pract Gastroenterol Hepatol
2006;3:
210–219.
9. Tutuian R, Castell DO. Review article: complete gastro-oesophageal reflux
monitoring—combined pH and impedance.
Aliment Pharmacol Ther
2006;24 (suppl 2):27–37.
10. Agrawal A, Castell DO. Clinical importance of impedance measurements.
J Clin Gastroenterol
2008;42:579–583.
11. Bredenoord AJ, Tutuian R, Smout AJ, Castell DO. Technology review:
esophageal impedance monitoring.
Am J Gastroenterol
2007;102:
187–194.
12. Mainie I, Tutuian R, Shay S, et al. Acid and non-acid reflux in patients
with persistent symptoms despite acid suppressive therapy: a multi-
centre study using combined ambulatory impedance-pH monitoring.
Gut
2006;55:1398–1402.
13. Zerbib F, Roman S, Ropert A, et al. Esophageal pH-impedance monitoring
and symptom analysis in GERD: a study in patients off and on therapy.
Am J Gastroenterol
2006;101:1956–1963.
14. DeVault KR, Castell DO. Updated guidelines for the diagnosis and treat-
ment of gastroesophageal reflux disease.
Am J Gastroenterol
2005;100:
190–200.
15. Kahrilas PJ, Shaheen NJ, Vaezi MF, et al. American Gastroenterological
Association Medical Position Statement on the management of gastro-
esophageal reflux disease.
Gastroenterology
2008;135:1383–1391, 91
e1–5.
16. Park W, Hicks DM, Khandwala F, et al. Laryngopharyngeal reflux: pro-
spective cohort study evaluating optimal dose of proton-pump inhibitor
therapy and pretherapy predictors of response.
Laryngoscope
2005;115:
1230–1238.
17. Lundell LR, Dent J, Bennett JR, et al. Endoscopic assessment of oesopha-
gitis: clinical and functional correlates and further validation of the Los
Angeles classification.
Gut
1999;45:172–180.
18. Pandolfino JE, Richter JE, Ours T, Guardino JM, Chapman J, Kahrilas
PJ. Ambulatory esophageal pH monitoring using a wireless system.
Am
J Gastroenterol
2003;98:740–749.
19. Zerbib F, des Varannes SB, Roman S, et al. Normal values and day-to-day
variability of 24-h ambulatory oesophageal impedance-pH monitoring in
a Belgian-French cohort of healthy subjects.
Aliment Pharmacol Ther
2005;22:1011–1021.
20. Shay S, Tutuian R, Sifrim D, et al. Twenty-four hour ambulatory simultane-
ous impedance and pH monitoring: a multicenter report of normal values
from 60 healthy volunteers.
Am J Gastroenterol
2004;99:1037–1043.
21. Pritchett JM, Aslam M, Slaughter JC, Ness RM, Garrett CG, Vaezi MF.
Efficacy of esophageal impedance/pH monitoring in patients with refrac-
tory gastroesophageal reflux disease, on and off therapy.
Clin Gastroen-
terol Hepatol
2009;7:743–748.
22. Tutuian R, Mainie I, Agrawal A, et al. Normal values for ambulatory 24-
hour combined impedance-pH monitoring on acid suppressive therapy.
Gastroenterology
2006;130:A171.
23. Mainie I, Tutuian R, Agrawal A, Adams D, Castell DO. Combined multi-
channel intraluminal impedance-pH monitoring to select patients with
persistent gastro-oesophageal reflux for laparoscopic Nissen fundoplica-
tion.
Br J Surg
2006;93:1483–1487.
24. Slaughter JC, Goutte M, Rymer JA, et al. Caution about overinterpreta-
tion of symptom indexes in reflux monitoring for refractory gastroesoph-
ageal reflux disease.
Clin Gastroenterol Hepatol
2011;9:868–874.
25. Vaezi MF, Higginbotham T, Kavitt RT, et al. Do patients report symptoms
when they occur? Fundamental consequences for interpretation of am-
bulatory reflux monitoring.
Gastroenterology
2012;142:S–415.
26. Francis DO, Goutte M, Slaughter JC, et al. Traditional reflux parameters
and not impedance monitoring predict outcome after fundoplication in
extraesophageal reflux.
Laryngoscope
2011;121:1902–1909.
27. Charbel S, Khandwala F, Vaezi MF. The role of esophageal pH monitoring
in symptomatic patients on PPI therapy.
Am J Gastroenterol
2005;100:
283–289.
28. Sloan S, Rademaker AW, Kahrilas PJ. Determinants of gastroesophageal
junction incompetence: hiatal hernia, lower esophageal sphincter, or
both?
Ann Intern Med
1992;117:977–982.
29. Jones MP, Sloan SS, Rabine JC, Ebert CC, Huang CF, Kahrilas PJ. Hiatal
hernia size is the dominant determinant of esophagitis presence and se-
verity in gastroesophageal reflux disease.
Am J Gastroenterol
2001;96:
1711–1717.
30. Vaezi MF, Richter JE. Role of acid and duodenogastroesophageal reflux in
gastroesophageal reflux disease.
Gastroenterology
1996;111:1192– 1199.
31. Zerbib F, Duriez A, Roman S, Capdepont M, Mion F. Determinants of gas-
tro-oesophageal reflux perception in patients with persistent symptoms
despite proton pump inhibitors.
Gut
2008;57:156–160.
Laryngoscope 123: October 2013
Kavitt et al.: The Role of Impedance Monitoring in Extraesophageal Symptoms
144